AMITYVILLE, N.Y.--(BUSINESS WIRE)--Dec. 11, 2012-- Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) today announced that it is scheduled to make an investor presentation at the Oppenheimer 23rd Annual Healthcare Conference Thursday, December 13, 2012, at 10:00 a.m. Eastern Time.
A live audio webcast of the Company's presentation can be accessed on the Investor Relations page of the Company's website:
http://www.hitechpharm.com
The webcast will be archived within one hour after the live event and...
AMITYVILLE, N.Y.--(BUSINESS WIRE)--Dec. 6, 2012-- Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) today reported results for the Company's fiscal second quarter ended October 31, 2012.
Quarterly Results
Net sales for the three months ended October 31, 2012 were $57,537,000, an increase of $662,000 compared to the net sales of $56,875,000 for the three months ended October 31, 2011.
Net sales for generic pharmaceuticals for the three months ended October 31, 2012 were $47,286,000, a decrease of ...
AMITYVILLE, N.Y.--(BUSINESS WIRE)--Nov. 30, 2012-- Hi-Tech Pharmacal Co., Inc. (NASDAQ:HITK) announced that it will pay a special one-time dividend of $1.50 per share. The dividend will be payable on December 28, 2012 to shareholders of record on December 13, 2012.
David Seltzer, President and CEO commented on the dividend: "This special dividend is the result of the success we have had over the last several years. It is also a reflection of our positive outlook and our Board's and management ...
AMITYVILLE, N.Y.--(BUSINESS WIRE)--Nov. 29, 2012-- Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) announced that the Company will release results for its second quarter of Fiscal Year 2012 ended October 31, 2012, prior to the market opening on Thursday December 6, 2012 and will hold a conference call to discuss its financial results at 10 a.m. Eastern Time.
To access the conference call, dial toll free 800-591-6944, or 617-614-4910 for international callers, five minutes before the conference. The...
AMITYVILLE, N.Y.--(BUSINESS WIRE)--Sep. 5, 2012-- Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) today reported results for the Company's fiscal first quarter ended July 31, 2012.
Quarterly Results
Net sales for the three months ended July 31, 2012 were $52,043,000, a decrease of $4,168,000 or 7% compared to the net sales of $56,211,000, for the three months ended July 31, 2011.
Net sales for generic pharmaceuticals for the three months ended July 31, 2012 were $45,922,000, a decrease of $3,04...
AMITYVILLE, N.Y.--(BUSINESS WIRE)--Sep. 4, 2012-- Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) announced that the Company will release results for its first quarter of Fiscal Year 2012 ended April 30, 2012, prior to the market opening on Wednesday September 5, 2012 and will hold a conference call to discuss its financial results at 10 a.m. Eastern Time.
To access the conference call, dial toll free 866-383-8008, or 617-597-5341 for international callers, five minutes before the conference. The p...
AMITYVILLE, N.Y.--(BUSINESS WIRE)--Aug. 13, 2012-- Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) today announced that it is scheduled to make an investor presentation at the Canaccord Genuity 32nd Annual Growth Conference Tuesday, August 14, 2012, at 2:30 p.m. Eastern Daylight Time.
A live audio webcast of the Company's presentation can be accessed on the Company's website:
http://www.hitechpharm.com
The webcast will be archived within one hour after the live event and will be available for 9...
AMITYVILLE, N.Y.--(BUSINESS WIRE)--Jul. 10, 2012-- Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) today reported results for the fourth quarter and year ended April 30, 2012.
Fourth Quarter Results
For the three months ended April 30, 2012, the Company reported net sales of $61.3 million, an increase of 7% from $57.2 million for the same period last year.
During the quarter ended April 30, 2012, net sales of generic pharmaceutical products were $52.7 million, an increase of 10% compared to $48...
AMITYVILLE, N.Y.--(BUSINESS WIRE)--Jul. 5, 2012-- Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) announced that the Company will release results for its fourth quarter of Fiscal Year 2012 ended April 30, 2012, prior to the market opening on Tuesday July 10, 2012 and will hold a conference call to discuss its financial results at 10 a.m. Eastern Time.
To access the conference call, dial toll free 866-730-5765, or 617-350-1589 for international callers, five minutes before the conference. The passco...
AMITYVILLE, N.Y.--(BUSINESS WIRE)--Jun. 4, 2012-- Hi-Tech Pharmacal Co., Inc. (NASDAQ:HITK) announced today the signing of a definitive agreement under which Hi-Tech acquired exclusive rights to the Cormax® brand from Watson Laboratories for an undisclosed sum of money. Cormax®, a branded version of clobetasol propionate topical solution 0.05%, is indicated for the treatment dermatoses of the scalp. The Cormax® brand will be sold through the Company's branded prescription subsidiary, ECR Pharmac...
AMITYVILLE, N.Y.--(BUSINESS WIRE)--Jun. 1, 2012-- Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) today announced that it is scheduled to make an investor presentation at the Jefferies 2012 Global Health Care Conference Monday, June 4, 2012, at 11:30 a.m. Eastern Daylight Time.
A live audio webcast of the Company's presentation can be accessed on the Company's website:
http://www.hitechpharm.com
The webcast will be archived within one hour after the live event and will be available for 90 days....
AMITYVILLE, N.Y.--(BUSINESS WIRE)--May. 14, 2012--
Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) today announced that it is
scheduled to make an investor presentation at the Bank of America
Merrill Lynch 2012 Health Care Conference Tuesday, May 15, 2012, at
10:40 p.m. Pacific Daylight Time. The conference is being held May 15 -
17, 2012, at The Encore at Wynn, Las Vegas, NV.
A live audio webcast of the Company's presentation can be accessed on
...
AMITYVILLE, N.Y., Apr 26, 2012 (BUSINESS WIRE) --Hi-Tech Pharmacal Co., Inc. (NASDAQ:HITK) announced today the signing of
a definitive agreement under which Hi-Tech acquired rights to market
generic Lidocaine 5% Ointment from Septodont, Inc. Lidocaine 5% Ointment
is indicated for use as a local anesthetic. Profits from the sale of the
product will be shared with Septodont. Lidocaine 5% Ointment had sales
of $25 million for the 12 month period ended Februar...
AMITYVILLE, N.Y.--(BUSINESS WIRE)--Mar. 8, 2012--
Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) today reported results for
the Company’s fiscal third quarter ended January 31, 2012.
Quarterly Results
Net sales for the three months ended January 31, 2012 were $55,625,000,
an increase of $5,925,000 or 12% compared to the net sales of
$49,700,000, for the three months ended January 31, 2011.
Net sales for generic pharmaceutic...
AMITYVILLE, N.Y.--(BUSINESS WIRE)--Mar. 8, 2012--
Hi-Tech Pharmacal Co., Inc. (NASDAQ:HITK) announced today the signing of
a definitive agreement under which Hi-Tech acquired several homeopathic
branded nasal spray products including Sinus Buster® and Allergy Buster®
from Dynova Laboratories, Inc. for $1.25 million in cash and an
additional $1.25 million deposited in an escrow account to pay for
certain expenses. Hi-Tech will also pay a royalty on Ne...
AMITYVILLE, N.Y.--(BUSINESS WIRE)--Mar. 2, 2012--
Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) announced that the Company
will release results for its third quarter of Fiscal Year 2012 ended
January 31, 2012, prior to the market opening on Thursday March 8, 2012
and will hold a conference call to discuss its financial results at 11
a.m. Eastern Time.
To access the conference call, dial toll free 866-825-3308, or
617-213-8062 for internat...
AMITYVILLE, N.Y.--(BUSINESS WIRE)--Feb. 29, 2012--
Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK), a specialty pharmaceuticals
company, announced today that the US Food and Drug Administration, (FDA)
granted final approval for the Company's Abbreviated New Drug
Application, (ANDA) for Levetiracetam oral solution 100mg/mL, the
generic for UCB Pharma’s Keppra ® oral solution which had combined brand
and generic sales of $62 million for the 12 months ended ...
AMITYVILLE, N.Y.--(BUSINESS WIRE)--Feb. 28, 2012--
Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) today announced that it is
scheduled to make an investor presentation at the 2012 RBC Capital
Markets’ Global Healthcare Conference at 10:00 AM on February 29, 2012.
The conference is being held February 28 - 29, 2012, at The New York
Palace Hotel in New York City.
A live audio webcast of the Company's presentation can be accessed on
the Compa...
AMITYVILLE, N.Y.--(BUSINESS WIRE)--Jan. 31, 2012--
Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK), a specialty pharmaceuticals
company, announced today that the US Food and Drug Administration, (FDA)
granted final approval for the Company's Abbreviated New Drug
Application, (ANDA) for Lorazepam oral concentrate 2mg/mL, the generic
for Roxanne’s Lorazepam Intensol® oral concentrate which had combined
brand and generic sales of $10 million for the 12 month...
AMITYVILLE, N.Y.--(BUSINESS WIRE)--Jan. 18, 2012--
Hi-Tech Pharmacal Co., Inc. (NASDAQ:HITK),
a specialty pharmaceuticals company, announced today that it has
acquired marketing and distribution rights to a topical wound gel
product from Glycobiosciences , Inc. The hyaluronic acid and emollient
based gel is a proprietary patented device approved by the FDA pursuant
to Section 510 (k). The product will be marketed under the brand name
Hylase® W...
Quotes delayed at least 15 minutes. Market data provided by Interactive Data.
